This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 643597.
ClinicalTrials.gov Identifier:
NCT02527629
News
ARISE closing meeting held on 1st of March 2019 in Hannover - Early results from the prospective European trial on cell-free allografts for aortic valve replacement
Aortic valve replacement (AVR) in children and young adult patients still constitutes a major problem as these young individuals face a difficult choice between a complex, multi-valve procedure such as the Ross-procedure and the... [more]
Patient lecture and seminar on regenerative heart valves and stem cell therapy options - 30.03.2019 in the Hannover Zoo
Patientenseminar: Regenerative Therapien und Stammzelltherapie bei angeborenen Herzfehlern – geht das schon? [more]
Welcome to ARISE
65,000 aortic valve replacements (AVR) are performed in Europe each year to treat acquired and congenital aortic valve diseases. Current AVR options are, however, limited for young patients - especially female patients - and those unwilling to accept life-long medical anticoagulation with its inherent risks. None of the currently available prostheses for AVR is tailored toward the individual patient or allows for individual regeneration. The ARISE project will bridge this therapeutic gap in a clinical study to determine the feasibility, safety and efficacy of regenerative heart valves for aortic valve replacement.